Higher, Fewer Copaxone Doses Lowered Relapse Rates Over 7 Years 

Higher, Fewer Copaxone Doses Lowered Relapse Rates Over 7 Years 

315145

Higher, Fewer Copaxone Doses Lowered Relapse Rates Over 7 Years 

A higher dose of Copaxone (glatiramer acetate) given three times weekly over seven years led to sustainably lower relapse rates and slowed disability progression in multiple sclerosis (MS) patients, according to a long-term analysis of the GALA study. The higher dose — 40 mg/mL — was generally well-tolerated with no new safety signals observed. These findings support the safe, long-term use of Copaxone in people with relapsing forms of MS, the scientists said. The study, “Long-term efficacy…

You must be logged in to read/download the full post.